The first four compounds demonstrated low nanomolar cell-free activities comparable to lapatinib in the primary screen, and promising low micromolar anti-proliferative actions against HER2 overexpressing breast cancer cell lines in the counter screen. This evidence concerns the gene ERBB2 and breast carcinoma.